Imunon Q2 net loss narrows to $5.6M; cash $24.1M; on track for COVID IND Q1 2024

Imunon, Inc.

2023-Q2 EPS reported -$1.28

Net loss Q2 2023 $5.6M ($0.61/sh) vs $6.0M ($0.87/sh) in Q2 2022; operating expenses down 10% YoY.
Cash and investments $24.1M at June 30, 2023; plus planned $1.8M from NOL sales; expected to fund operations through 2024.
On track to submit IND for seasonal COVID-19 vaccine (IMNN-101) in Q1 2024; FDA confirmed platform acceptability.
Unveiled new cGMP manufacturing facility at HudsonAlpha to support R&D and lower costs.
Preclinical data show PlaCCine vaccines elicit durable T-cell responses > 14 months, higher than mRNA vaccine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.